Breaking News Instant updates and real-time market news.

AAPL

Apple

$145.32

-3.66 (-2.46%)

, GE

General Electric

$29.01

1.065 (3.81%)

16:13
06/12/17
06/12
16:13
06/12/17
16:13

On The Fly: Top stock stories for Monday

Stocks began the session in negative territory and remained there throughout the day. The tech selloff that began on Friday continued today, pushing the Nasdaq to another daily loss of about 0.5%. The Dow and S&P closed lower too, but were helped to outperform the Nasdaq by shares of General Electric (GE), which were higher following the announcement its CEO will step down in August. Steel stocks also got a bit of a boost after comments from President Trump that the dumping by China would soon be handled. ECONOMIC EVENTS: In the U.S., the budget deficit widened to $88.4B in May, which is not far from the consensus forecast of $87B, but is a large deterioration from the $53B deficit in May of last year. COMPANY NEWS: Shares of Apple (AAPL) fell 2.5% after Mizuho analyst Abhey Lamba downgraded the stock to Neutral and lowered his price target for the shares to $150 from $160 saying "enthusiasm" around the upcoming iPhone launch is fully priced in after the stock's year-to-date outperformance... Meanwhile, General Electric shares rose 3.6% after the blue chip conglomerate reported that longtime CEO Jeff Immelt plans to retire at year end. John Flannery, the current President and CEO of GE Healthcare, has been named CEO of the company effective August 1, and Chairman and CEO effective January 1, 2018. In other GE news, the company and Baker Hughes (BHI) announced that they have reached an agreement with the Department of Justice that would allow the parties to complete their proposed transaction. Baker Hughes has scheduled its shareholders vote for June 30 and the companies continue to target a mid-year close... Bloomberg reported that Syngenta (SYT) and BASF (BASFY) are among companies that have submitted preliminary bids for assets that Bayer (BAYRY) plans to divest in secure approval for its takeover of Monsanto (MON). Such businesses offered include cottonseeds, canola, the LibertyLink herbicide-resistant trait, and the company's glufosinate weed killer, sources told Bloomberg. MAJOR MOVERS: Among the notable gainers was QIWI (QIWI), which advanced 3% after shareholder Otkritie said it intends to make a cash tender offer for up to nearly 25M outstanding Class B ordinary shares at a price of $28 per share. Also higher was Halyard Health (HYH), which gained 3% after Reuters reported that the company was exploring a sale of its surgical and infection prevention unit. Among the noteworthy losers was Coherus Biosciences (CHRS), which dropped nearly 24% after the FDA issued a complete response letter for its biosimilar version of Amgen's (AMGN) Neulasta. Also lower was Penn Virginia (PVAC), which slipped 2% after Reuters reported that the company has hired an investment bank to help it explore a possible sale to help its creditors exit following the company's recent bankruptcy restructuring. INDEXES: The Dow fell 36.30, or 0.17%, to 21,235.67, the Nasdaq lost 32.45, or 0.52%, to 6,175.46, and the S&P 500 declined 2.38, or 0.1%, to 2,429.39.

AAPL

Apple

$145.32

-3.66 (-2.46%)

GE

General Electric

$29.01

1.065 (3.81%)

BHI

Changed to BHGE

$56.12

0.585 (1.05%)

SYT

Syngenta

$91.92

0.02 (0.02%)

BASFY

BASF

$96.49

-0.13 (-0.13%)

BAYRY

Bayer

$133.06

0.01 (0.01%)

MON

Monsanto

$117.75

0.23 (0.20%)

QIWI

QIWI

$24.28

0.75 (3.19%)

HYH

Halyard Health

$39.24

1.15 (3.02%)

CHRS

Coherus Biosciences

$15.75

-4.9 (-23.73%)

AMGN

Amgen

$164.88

0.82 (0.50%)

PVAC

Penn Virginia

$42.66

-0.91 (-2.09%)

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 13

    Jun

  • 15

    Jun

  • 20

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 19

    Jul

  • 14

    Aug

  • 02

    Oct

AAPL Apple
$145.32

-3.66 (-2.46%)

06/11/17
MZHO
06/11/17
DOWNGRADE
Target $150
MZHO
Neutral
Apple downgraded to Neutral from Buy at Mizuho
Mizuho analyst Abhey Lamba downgraded Apple to Neutral from Buy and lowered his price target for the shares to $150 from $160. The iPhone maker fell along with the Nasdaq index late in Friday's trade to close down 4%, or $6.01, to $148.98. "Enthusiasm" around the upcoming iPhone launch is fully priced in after the stock's year-to-date outperformance, Lamba wrote to investors Sunday night. The analyst sees limited upside to consensus estimates and notes Apple shares are trading near the upper-end of their recent valuation range.
06/12/17
BERN
06/12/17
NO CHANGE
BERN
Apple slowdown in China probably a temporary pause, says Bernstein
Bernstein analyst A.M. (Toni) Sacconaghi, Jr. says that weakening sales of Apple's iPhone in China is probably due to a temporary pause in demand ahead of the company's new iPhone scheduled to debut later this year, rather than a result of competition from other high-end devices. The analyst continues to believe that Apple's risk/reward ratio is attractive and keeps a $160 price target and Outperform rating on the stock.
06/07/17
RBCM
06/07/17
NO CHANGE
RBCM
Analog Devices weakness will be short lived, says RBC Capital
RBC Capital analyst Amit Daryanani notes that Analog Devices (ADI) "has underperformed rather notably" since its Q2 results on May 31. The analyst blames the weakness on the company's reduced revenue from Apple (AAPL). However, he thinks that investors will begin focusing more on the company's multiple tailwinds, possibly starting in the wake of its June 20 Analyst Day. Consequently, he expects the stock to rise from current levels and keeps a $92 price target and Outperform rating on the shares.
06/07/17
ARGS
06/07/17
NO CHANGE
ARGS
Apple price target raised to $175 from $160 at Argus
Argus analyst Jim Kelleher increased his price target on Apple after the company annoucned new products and product enhancements. The analyst quotes Apple bears as saying that the company is "playing catch-up" by introducing similar products to those that its rivals have already launched. However, Kelleher says that, "coming late to the party did not hurt iPhone's leadership in smartphones." He keeps a Buy rating on the shares. .
GE General Electric
$29.01

1.065 (3.81%)

05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/12/17
05/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the stock is overvalued given "weak earnings quality" and the "wide gap between non-cash and cash earnings." 2. Electronic Arts (EA) was downgraded to Neutral from Long-Term Buy at Hilliard Lyons and to Sell from Hold at Deutsche Bank. 3. Uni-Pixel (UNXL) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying while he sees abundant industry demand and interest for the company's products, he sees Uni-Pixel's future as somewhat binary and dependent upon strategic partnerships being executed relatively quickly. Alger also lowered his price target on the shares to 45c from $2. 4. Akari Therapeutics (AKTX) downgraded to Market Perform from Outperform at William Blair with analyst Tim Lugo citing the company's announcement that it placed its Chief Executive Officer on administrative leave as it reviews any involvement with the Edison Report. 5. Mazor Robotics (MZOR) downgraded to Market Perform from Outperform at JMP Securities with analyst David Turkaly citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
BHI Changed to BHGE
$56.12

0.585 (1.05%)

04/19/17
04/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ING Group (ING) initiated with a Buy at Jefferies. 2. T-Mobile (TMUS) was initiated with a Buy at SunTrust while Sprint (S), Verizon (VZ), and AT&T (T) were initiated with a Hold. 3. DXC Technology (DXC) initiated with an Overweight at JPMorgan. 4. LendingClub (LC) coverage resumed with a Hold at Stifel. 5. Halliburton (HAL) and Schlumberger (SLB) were initiated with a Buy at HSBC while Baker Hughes (BHI) was initiated with a Hold. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/17
BMOC
04/26/17
DOWNGRADE
BMOC
Market Perform
Baker Hughes downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Daniel Boyd downgraded Baker Hughes to Market Perform and lowered its price target to $65 from $69 to reflect earnings risk. Boyd's estimates are below consensus and guidance as he expects EBITDA growth to disappoint due to disadvantaged cycle mix and near-term execution risk. The analyst likes potential deal synergies upside but thinks buyback expectations of up to 12% of pro forma market cap is possible, but unlikely.
04/26/17
FBCO
04/26/17
NO CHANGE
Target $53
FBCO
Neutral
Baker Hughes price target lowered to $53 from $65 at Credit Suisse
Credit Suisse analyst James Wicklund lowered his price target for Baker Hughes to $53 from $65 following quarterly results. The analyst reiterates a Neutral rating on the shares.
04/19/17
HSBC
04/19/17
INITIATION
Target $62
HSBC
Hold
Baker Hughes initiated with a Hold at HSBC
HSBC analyst David Phillips initiated Baker Hughes with a Hold and a $62 price target due to valuation and said there are few impediments to the GE merger completion.
SYT Syngenta
$91.92

0.02 (0.02%)

03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
09/06/16
BERN
09/06/16
DOWNGRADE
BERN
Market Perform
Syngenta downgraded on valuation, anticipated deal delay at Bernstein
As noted earlier, Bernstein downgraded Syngenta to Market Perform from Outperform. As reasons for the downgrade, analyst Jeremy Redenius cited valuation and his belief that regulatory approvals for the company's acquisition by ChemChina could be delayed until 2017. Target to $92.20 from $90.20.
02/16/17
JEFF
02/16/17
DOWNGRADE
JEFF
Hold
Syngenta downgraded to Hold from Buy at Jefferies
Jefferies analyst Laurence Alexander downgraded Syngenta to Hold with an unchanged price target of CHF 445.
12/09/16
RAJA
12/09/16
UPGRADE
RAJA
Strong Buy
Syngenta upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Patrick Lambert upgraded Syngenta to Strong Buy.
BASFY BASF
$96.49

-0.13 (-0.13%)

07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
Monsanto needs over $135/share bid to shut down alternatives, says Jefferies
After media reports indicated that Monsanto (MON) has revived talks with BASF (BASFY) as an alternative to the offer from Bayer (BAYRY), Jefferies analyst Laurence Alexander said he believes Bayer would need to increase its bid to over $135 per share for Monsanto to shut down its consideration of alternatives. The analyst views Bayer as "the best technology and market position fit for Monsanto," but adds that BASF "would have significantly less antitrust concerns."
10/05/16
UBSW
10/05/16
UPGRADE
UBSW
Buy
BASF upgraded to Buy from Neutral at UBS
02/13/17
EVER
02/13/17
INITIATION
EVER
Buy
BASF initiated with a Buy at Evercore ISI
Evercore ISI analyst Laurent Favre initiated BASF with a Buy rating and a EUR100 price target.
01/19/17
JPMS
01/19/17
UPGRADE
JPMS
Overweight
BASF upgraded to Overweight from Underweight at JPMorgan
JPMorgan analyst Martin Evans yesterday double upgraded BASF to Overweight from Underweight saying he's turning more positive on European Chemicals.
BAYRY Bayer
$133.06

0.01 (0.01%)

01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
MON Monsanto
$117.75

0.23 (0.20%)

02/23/17
02/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Monsanto (MON) initiated with a Sector Perform at RBC Capital. 2. FMC Corporation (FMC) initiated with an Outperform at RBC Capital. 3. OncoCyte (OCX) initiated with a Buy at Chardan. 4. Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Evercore ISI. 5. Reata Pharmaceuticals (RETA) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/23/17
RBCM
02/23/17
INITIATION
RBCM
Sector Perform
Monsanto initiated with a Sector Perform at RBC Capital
RBc Capital analyst Arun Viswanathan says that ,"given challenging agricultural conditions, Monsanto lacks catalysts. Target $118.
QIWI QIWI
$24.28

0.75 (3.19%)

01/18/17
JPMS
01/18/17
NO CHANGE
JPMS
QIWI's Sberbank revenue could be at risk, says JPMorgan
JPMorgan said Alibaba's (BABA) AliExpress is int talks with Sberbank over a joint-venture in Russia. The firm's analyst estimates 20% of QIWI's (QIWI) ecommerce revenue is generated from physical e-commerce, about 6% of total revenue, and AliExpress is responsible for a majority of that generated revenue. A joint-venture would mean all the payment processing would likely go through Sberbank's own platform, the firm's analyst believes.
04/10/17
JPMS
04/10/17
UPGRADE
Target $23
JPMS
Overweight
QIWI upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alexei Gogolev upgraded QIWI to Overweight saying the company is "finally turning the corner" after six quarters of single-digit sales growth. The improving macro environment and consumer sentiment are likely to boost core business operations, the analyst contends. Gogolev raised his price target for the shares to $23 from $15.
HYH Halyard Health
$39.24

1.15 (3.02%)

02/28/17
SPHN
02/28/17
DOWNGRADE
SPHN
Equal Weight
Halyard Health downgraded to Equal Weight from Overweight at Stephens
01/06/17
01/06/17
DOWNGRADE

Market Perform
Halyard Health downgraded to Market Perform at JMP Securities
As previously reported, JMP Securities analyst David Turkaly downgraded Halyard Health (HYH) to Market Perform from Outperform as he sees less near-term upside to the shares following strong performance of the stock at the end of 2016. In conjunction with a review of his Medical Devices and Supplies industry coverage, Turkaly also upgraded Integra LifeSciences (IART) to an Outperform rating this morning.
01/06/17
JMPS
01/06/17
DOWNGRADE
JMPS
Market Perform
Halyard Health downgraded to Market Perform from Outperform at JMP Securities
01/06/17
JMPS
01/06/17
UPGRADE
JMPS
Outperform
Integra LifeSciences upgraded to Outperform at JMP Securities
As previously reported, JMP Securities analyst David Turkaly upgraded Integra LifeSciences (IART) to Outperform from Market Perform as he believes its recent fundamental performance is sustainable after the company streamlined its portfolio to become faster growing and regenerative medicine focused. In conjunction with a review of his Medical Devices and Supplies industry coverage, Turkaly also downgraded Halyard Health (HYH) to Market Perform this morning.
CHRS Coherus Biosciences
$15.75

-4.9 (-23.73%)

06/12/17
LEER
06/12/17
NO CHANGE
Target $161
LEER
Market Perform
Amgen price target raised to $161 on Neulasta biosimilar delay at Leerink
Leerink analyst Geoffrey Porges noted that Coherus Biosciences (CHRS) received a complete response letter from the FDA for its biosimilar to Amgen's (AMGN) Neulasta, which he views as likely delaying its launch by at least a year. However, the "windfall" is offset by the Supreme Court decision that "effectively eliminates" the 6-month delay for biosimilars associated with notification, Porges tells investors. Based on his forecast for a six-month delay in the timing of a Neulasta biosimilar launch in the U.S., to the second quarter of 2018 from the fourth quarter of 2017, Porges increased his 2018 Amgen revenue forecast by $500M and raised his price target to $161 from $159, though he keeps a Market Perform rating on the stock.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $33
SBSH
Buy
Coherus price target lowered to $33 after complete response letter at Citi
Citi analyst Mohit Bansal, in an intraday follow up note on Coherus Biosciences, lowered his price target on the stock to $33 from $38, stating that the CRL for its Neulasta biosimilar creates uncertainty and delays the product's potential launch by about one year. The analyst, who noted that a positive Supreme Court decision today eliminates a 180 day notice after approval and could expedite launch for the drug by six months, keeps a Buy rating on Coherus shares.
06/12/17
JPMS
06/12/17
NO CHANGE
JPMS
Overweight
Coherus shares can hit $30-plus on 2018 approval, says JPMorgan
JPMorgan analyst Chris Schott said that while today's news from Coherus Biosciences of a complete response letter on CHS-1701 is "clearly disappointing," the letter appears "very much addressable." The FDA is requesting reanalysis of a subset of samples using a more sensitive immunogenicity assay, which likely will result in a one year delay in approval, Schott told investors earlier in a research note. He notes the FDA did not request additional clinical studies. Schott continues to believe CHRS-1701 will be one of the first approved biosimilar versions of Neulasta. He views today's selloff in Coherus shares as an overreaction and keeps an Overweight rating on the name. The analyst sees upside to $30 per share assuming CHS-1701 gets approved in 2018. Coherus in afternoon trading is down 27% to $14.98.
06/12/17
COWN
06/12/17
NO CHANGE
Target $45
COWN
Outperform
Coherus Biosciences CHS-1701 CRL 'appears resolvable', says Cowen
Cowen analyst Ken Cacciatore said Coherus Biosciences' CHS-1701 CRL "appears resolvable," with a delay most likely being a year. There does not seem to be any specific issue with 1701, but the FDA would like further analysis with a more refined assay to ensure the highest quality possible, the analyst wrote. Cacciatore rates Coherus a Buy with a $45 price target.
AMGN Amgen
$164.88

0.82 (0.50%)

05/22/17
FBCO
05/22/17
NO CHANGE
Target $177
FBCO
Neutral
Amgen romosozumab U.S. approval in July 'off the table,' says Credit Suisse
After Amgen (AMGN) and UCB (UCBJY) announced that the Evenity "ARCH" study met both primary endpoints but that there was also a newly observed cardiovascular safety signal in the trial, Credit Suisse analyst Alethia Young said any potential U.S. approval by the drug's July 19 PDUFA date is "off the table" and it is unclear as of now what U.S. approval timelines may be. She reduced her probability of success for romosozumab to 80% from 100% and lowered her price target on Amgen to $177 from $178. Young keeps a Neutral rating on Amgen shares.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
PVAC Penn Virginia
$42.66

-0.91 (-2.09%)

03/15/17
JRCO
03/15/17
INITIATION
JRCO
Buy
Penn Virginia initiated with a Buy at Johnson Rice
Johnson Rice analyst Welles Fitzpatrick started Penn Virginia with a Buy rating.
03/31/17
ADAM
03/31/17
INITIATION
Target $49
ADAM
Hold
Penn Virginia reinstated with a Hold at Canaccord
Canaccord analyst Stephen Berman re-initiated coverage on Penn Virginia with a Hold and a $49 price target citing valuation and low relative trading liquidity.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$98.12

1.92 (2.00%)

13:55
09/21/17
09/21
13:55
09/21/17
13:55
Recommendations
Intercept analyst commentary  »

FDA communication on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICPT

Intercept

$98.12

1.92 (2.00%)

13:54
09/21/17
09/21
13:54
09/21/17
13:54
Recommendations
Intercept analyst commentary  »

Intercept selloff on FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$19.27

-0.5 (-2.53%)

13:50
09/21/17
09/21
13:50
09/21/17
13:50
Options
Kinder Morgan attracts call writers as shares slump »

Kinder Morgan attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.85

0.71 (7.77%)

13:45
09/21/17
09/21
13:45
09/21/17
13:45
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

13:45
09/21/17
09/21
13:45
09/21/17
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ICPT

Intercept

$98.12

1.92 (2.00%)

13:41
09/21/17
09/21
13:41
09/21/17
13:41
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/21/17
09/21
13:40
09/21/17
13:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:39
09/21/17
09/21
13:39
09/21/17
13:39
Technical Analysis
Technical View: Hudson Technologies down on cautious Seeking Alpha mention »

The shares have taken a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HDSN

Hudson Technologies

$9.26

-0.03 (-0.32%)

13:34
09/21/17
09/21
13:34
09/21/17
13:34
Periodicals
Hudson Technologies mentioned cautiously by Seeking Alpha contributor 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

, LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

13:30
09/21/17
09/21
13:30
09/21/17
13:30
Hot Stocks
Before the Move: Watch Outfront Media ahead of NYC-MTA contract decision »

A decision regarding the…

OUT

Outfront Media

$21.19

-0.2 (-0.94%)

LAMR

Lamar Advertising

$64.42

0.45 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ILG

ILG

$25.87

0.56 (2.21%)

, VAC

Marriott Vacations

$119.30

5.31 (4.66%)

13:24
09/21/17
09/21
13:24
09/21/17
13:24
Periodicals
FrontFour plans ILG proxy fight if deal not struck this year, Bloomberg says »

FrontFour Capital, a…

ILG

ILG

$25.87

0.56 (2.21%)

VAC

Marriott Vacations

$119.30

5.31 (4.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

, TSLA

Tesla

$373.91

-1.19 (-0.32%)

13:21
09/21/17
09/21
13:21
09/21/17
13:21
Hot Stocks
Mercedes-Benz to start production of electric passenger cars in U.S. »

Mercedes-Benz will set up…

DDAIF

Daimler AG

$79.46

-0.16 (-0.20%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MSFT

Microsoft

$74.94

-0.5 (-0.66%)

13:20
09/21/17
09/21
13:20
09/21/17
13:20
Options
Notable call write in Microsoft »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

13:17
09/21/17
09/21
13:17
09/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/21/17
09/21
13:16
09/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
09/21/17
09/21
13:15
09/21/17
13:15
General news
Treasury's $11 B 10-year TIPS reopening was poorly received »

Treasury's $11 B…

XOP

SPDR Oil Exploration and Production Fund

$32.88

0.02 (0.06%)

13:10
09/21/17
09/21
13:10
09/21/17
13:10
Options
Hefty put spread in SPDR Oil and Gas Exploration ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$43.92

0.32 (0.73%)

13:05
09/21/17
09/21
13:05
09/21/17
13:05
Options
TripAdvisor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:04
09/21/17
09/21
13:04
09/21/17
13:04
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

ZGNX

Zogenix

$13.60

-0.95 (-6.53%)

12:55
09/21/17
09/21
12:55
09/21/17
12:55
Options
Zogenix put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$21.55

0.6 (2.86%)

12:51
09/21/17
09/21
12:51
09/21/17
12:51
Periodicals
Impax merger with Amneal could come next month, WSJ reports »

Impax and Amneal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAR

Avis Budget

$37.92

1.28 (3.49%)

12:40
09/21/17
09/21
12:40
09/21/17
12:40
Options
Avis attracts a put buyer »

Avis attracts a put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

12:40
09/21/17
09/21
12:40
09/21/17
12:40
General news
Treasury 10-year TIPS preview »

Treasury 10-year TIPS…

GIS

General Mills

$51.80

-0.3658 (-0.70%)

12:30
09/21/17
09/21
12:30
09/21/17
12:30
Options
Position adjustment in General Mills after earnings »

Position adjustment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.